EydisBio: Funding, Investors & Team (Oct 2026)
EydisBio, Inc. is an early-stage biopharmaceutical company focused on developing potent and selective small molecule therapeutics targeting autoimmune and inflammatory disease with high unmet medical needs. EydisBio's TAK1 inhibitor program is primarily focused on targeting the over 40% of rheumatoid arthritis patients who either do not respond or lose response over time to approved anti-TNF biologics. Our highly potent and exquisitely selective, orally bioavailable TAK1 inhibitors are also being explored in additional autoimmune indications including the rare disease systemic sclerosis, viral-induced acute respiratory distress syndrome, and as an alternative to opioids in patients with chronic pain. We also have an oncology discovery program with promising early efficacy in treating patients with FLT3 mutation-positive AML and glioblastoma.
EydisBio has raised $3.1M across 2 funding rounds on record, the most recent an undisclosed round of $500k announced in Oct 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EydisBio Company Profile and Key Stats
Latest funding round on record: Oct 2024.
EydisBio Funding Rounds
EydisBio raised $2.6M in an undisclosed round announced in Aug 2024.
2 months later, an undisclosed round of $500k was announced in Oct 2024.
EydisBio Founders and Leadership Team
No contact details are on record for this team yet.
EydisBio Funding Compared to Other Biotechnology Startups
EydisBio's latest round of $500k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EydisBio in Biotechnology and Durham
Companies Similar to EydisBio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
EydisBio Funding FAQs
What does EydisBio do?
EydisBio, Inc. is an early-stage biopharmaceutical company focused on developing potent and selective small molecule therapeutics targeting autoimmune and inflammatory disease with high unmet medical needs. EydisBio's TAK1 inhibitor program is primarily focused on targeting the over 40% of rheumatoid arthritis patients who either do not respond or lose response over time to approved anti-TNF biologics. Our highly potent and exquisitely selective, orally bioavailable TAK1 inhibitors are also being explored in additional autoimmune indications including the rare disease systemic sclerosis, viral-induced acute respiratory distress syndrome, and as an alternative to opioids in patients with chronic pain. We also have an oncology discovery program with promising early efficacy in treating patients with FLT3 mutation-positive AML and glioblastoma.
How much funding has EydisBio raised?
EydisBio has raised $3.1M across 2 rounds on record. The most recent is an undisclosed round of $500k announced in Oct 2024.
When did EydisBio last raise funding?
EydisBio's most recent funding round on record is an undisclosed round of $500k, announced in Oct 2024.
Who founded EydisBio?
FundedIQ lists Philip Hughes (Founder) at EydisBio.
Where is EydisBio headquartered?
EydisBio is based in Durham, North Carolina, United States.
How many employees does EydisBio have?
EydisBio is in the 1-10 employee band.
How does EydisBio's funding compare to other Biotechnology startups?
EydisBio's latest round of $500k is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's EydisBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EydisBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.